Allergy & Immunology
Systemic treatments for eczema: A network meta‐analysis
4 Oct, 2020 | 22:45h | UTCSystemic treatments for eczema: a network meta‐analysis – Cochrane Library
What does it mean if a vaccine is ‘successful’?
2 Oct, 2020 | 09:25h | UTCWhat Does It Mean If a Vaccine Is ‘Successful’? – Wired
‘Provocative results’ boost hopes of antibody treatment for COVID-19
2 Oct, 2020 | 09:21h | UTC‘Provocative results’ boost hopes of antibody treatment for COVID-19 – Science
Proposed clinical criteria for COVID-19-associated hyperinflammatory syndrome
30 Sep, 2020 | 09:50h | UTC
Commentary on Twitter
Defining and grading the clinical hyperinflammatory syndrome with #COVID19 and how this cytokine storm relates to outcomes https://t.co/6Ngp3OHZJx @TheLancetRheum @Intermountain pic.twitter.com/bDGwKpjOI4
— Eric Topol (@EricTopol) September 29, 2020
Investigational COVID-19 vaccine well-tolerated and generates immune response in older adults
30 Sep, 2020 | 09:36h | UTCOriginal Article: Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults – New England Journal of Medicine
Commentary on Twitter
The Moderna mRNA vaccine, which elicited antibodies and T cells specific for the Covid-19 virus in adults 55 years of age or younger, elicited similarly high levels of neutralizing-antibody and CD4 T-cell responses in older adults. #COVID19 #SARSCoV2
— NEJM (@NEJM) September 29, 2020
Less than 10% of US population has COVID-19 antibodies, data show
29 Sep, 2020 | 10:12h | UTCLess than 10% of US population has COVID-19 antibodies, data show – CIDRAP
Original Study: Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study – The Lancet
Commentary on Twitter
NEW Research—Nationwide cross-sectional analysis of US patients receiving dialysis finds fewer than 10% of people had #COVID19 antibodies by July 2020, and fewer than 10% of those with antibodies had been diagnosed by antigen or PCR testing https://t.co/QWPMO0gCr3 pic.twitter.com/v2K66uLLID
— The Lancet (@TheLancet) September 26, 2020
COVID-vaccine results are on the way — and scientists’ concerns are growing
28 Sep, 2020 | 01:33h | UTCCOVID-vaccine results are on the way — and scientists’ concerns are growing – Nature
Commentary on Twitter
Several ongoing coronavirus-vaccine trials could announce game-changing results next month. Scientists, though, have growing concerns. Here are the three areas they are watching closely. https://t.co/QxyA1zM0rY
— Nature (@nature) September 26, 2020
Britain will ‘host world’s first Covid-19 vaccine challenge trial’
24 Sep, 2020 | 09:22h | UTC
How close is a coronavirus vaccine?
24 Sep, 2020 | 09:25h | UTCHow close is a coronavirus vaccine? – Financial Times
Commentary on Twitter
A very good infographic on the #SARSCoV2 vaccineshttps://t.co/iIXQPUEecN @FT via @NChildersMEP
1. What is a Phase 3 trial? Number of events, efficacy pic.twitter.com/tbwtdOOYoB— Eric Topol (@EricTopol) September 24, 2020
What COVID-19 reinfection means for vaccines
24 Sep, 2020 | 09:23h | UTCWhat COVID-19 Reinfection Means for Vaccines – Scientific American
Long-term COVID-19 containment will be shaped by strength, duration of immunity
23 Sep, 2020 | 14:51h | UTCOriginal Article: Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years – Science
NICE Guideline: Antimicrobial prescribing for insect bites and stings
23 Sep, 2020 | 14:40h | UTC
What can we expect from first-generation COVID-19 vaccines?
22 Sep, 2020 | 10:02h | UTCWhat can we expect from first-generation COVID-19 vaccines? – The Lancet
Commentary on Twitter
We need to calibrate our expectations for the 1st generation of #SARSCoV2 vaccines https://t.co/QTJbyOd9xQ @TheLancet by @gmleunghku and Malik Peiris @hkumed Pe-covid normalcy is not near. pic.twitter.com/Y15TqfoRlf
— Eric Topol (@EricTopol) September 21, 2020
Editorial: Convalescent plasma for Covid-19
20 Sep, 2020 | 21:29h | UTCConvalescent plasma for covid-19 – The BMJ
Commentary on Twitter
Last month the US FDA authorised the emergency use of convalescent plasma for hospital patients with covid-19. What evidence underpinned the FDA’s controversial decision? And will the authorisation make it more difficult to recruit participants for RCTS? https://t.co/PMO13J2IOq
— The BMJ (@bmj_latest) September 19, 2020
Covid-19: Do many people have pre-existing immunity?
18 Sep, 2020 | 09:41h | UTCCovid-19: Do many people have pre-existing immunity? – The BMJ
Commentary on Twitter
It seemed a truth universally acknowledged that the human population had no pre-existing immunity to SARS-CoV-2, but is that actually the case? Peter Doshi explores the emerging research on immunological responseshttps://t.co/6LYRjxlWBQ
— The BMJ (@bmj_latest) September 17, 2020
Change in antibodies to SARS-CoV-2 over 60 days among health care personnel
18 Sep, 2020 | 09:32h | UTC
Commentary on Twitter
In this cohort study, anti–SARS-CoV-2 antibodies decreased over 60d in HCWs w 58% becoming seronegative. The results suggest that x-sectional seroprevalence studies may underestimate rates of prior infections because Abs may only be transiently detectable https://t.co/IHgURuDJYm
— JAMA (@JAMA_current) September 18, 2020
[Press release – not published yet] Eli Lilly reports first, promising results for an antibody against COVID-19
17 Sep, 2020 | 09:28h | UTCEli Lilly reports first, promising results for an antibody against COVID-19 – Science
Press release: Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting
Multisystem effects of COVID-19: A concise review for practitioners
16 Sep, 2020 | 09:14h | UTCMultisystem effects of COVID-19: A concise review for practitioners – Postgraduate Medicine
The lasting misery of coronavirus long-haulers
15 Sep, 2020 | 09:05h | UTCThe lasting misery of coronavirus long-haulers – Nature
Viewpoint: COVID-19 and the path to immunity
14 Sep, 2020 | 01:20h | UTCCOVID-19 and the Path to Immunity – JAMA
Commentary on Twitter
Declines in SARSCoV2 IgG neutralizing Abs raise concerns of susceptibility to reinfection. But acute Ab levels always decline post-infection, and Ab recall responses come from a pool of long-lived memory B cells https://t.co/geGOQkhdw2
— JAMA (@JAMA_current) September 12, 2020
COVID-19 herd immunity: Where are we?
14 Sep, 2020 | 01:18h | UTCCOVID-19 herd immunity: where are we? – Nature Reviews Immunology
Commentary on Twitter
This is one of the most succinct and best written short pieces on herd immunity, what it is and where we are heading with #COVID19.
If not comfortable with math, just get through the first sentences and it’s worth continuing the read. https://t.co/1F3MuQWkfc
— Michael Mina (@michaelmina_lab) September 13, 2020
The underdog coronavirus vaccines that the world will need if front runners stumble
11 Sep, 2020 | 01:20h | UTCThe underdog coronavirus vaccines that the world will need if front runners stumble – Nature
Opinion: Halting the Oxford vaccine trial doesn’t mean it’s not safe – it shows they’re following the right process
10 Sep, 2020 | 09:42h | UTC
A leading coronavirus vaccine trial is on hold: Scientists react
10 Sep, 2020 | 09:43h | UTCA leading coronavirus vaccine trial is on hold: scientists react – Nature
‘Everyone was left to guess what went wrong’: An open letter to AstraZeneca’s CEO on transparency
10 Sep, 2020 | 09:40h | UTC
Commentary on Twitter
Opinion: "In the middle of a pandemic — when the whole world, literally, is hoping a useful vaccine is on the horizon — everyone was left to guess what went wrong and what it might mean," @Pharmalot writes. https://t.co/jOpMyxC1dQ
— STAT (@statnews) September 9, 2020